Pfizer

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

22 Nov 2025

PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care (surgery alone) in cisplatin-ineligible patien

Pfizer Completes Acquisition of Metsera

14 Nov 2025

Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape Complements and transforms Pfizer’s Internal Medicine portfolio Positions P

Pfizer Responds to Delaware Chancery Court Ruling

08 Nov 2025

Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. f

Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement

01 Nov 2025

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach o

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

01 Nov 2025

Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended

Pfizer Addresses Proposal for Metsera

30 Oct 2025

Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant marke

Pfizer shares new survival data in non-metastatic prostate cancer

22 Oct 2025

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk

New long-term survival data in advanced lung cancer

22 Oct 2025

BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after approxi

Unprecedented survival data in muscle-invasive bladder cancer

22 Oct 2025

TOKYO AND NEW YORK, October 18, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phas

TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial

14 Oct 2025

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® (tucatinib) in patien

View details about the software product Informachine News Trackers